[1,3] dioxolo [4,5-g] [1,2,4] triazolo [1,5-a] quinoline derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer
AssigneeTrustees of Boston University
InventorsScott E. Schaus, Ulla Hansen, Joshua A. Bishop
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to [1,3]dioxolo[4,5-g]quinoline-6(5H)thione and [1,3]dioxolo[4,5-g][1,2,4]triazolo[1,5-a]quinoline derivatives and/or compositions for use in inhibiting, preventing and/or treating cancer, e.g. hepatocellular carcionoma (HCC). In some embodiments, the invention relates to the use of small-molecule compounds to inhibit, prevent and/or treat expression of the transcription factor Late SV40 Factor (LSF) for treatment of HCC or other cancer types.
Claims10
A compound of structural formula XIV, XV or XVI;
- or a pharmaceutically acceptable salt thereof wherein,
- each X is independently O or S;
- R1 is hydrogen or an alkyl, alkenyl, alkynyl, aryl, heteroaryl or arylalkyl group;
- R2 is hydrogen or a hydroxyl, alkoxy, phenoxy, alkyl, alkenyl, alkynyl, aryl, heteroaryl or arylalkyl group;
- each R3 and each R6 is:
- (i) independently hydrogen, fluorine, chlorine, bromine, iodine or a hydroxyl, alkoxy, phenoxy, alkyl, alkenyl, alkynyl, aryl, heteroaryl or arylalkyl group;
- or (ii) the two R6 moieties and/or the two R3 moieties taken together with an alkylene, alkenylene or alkynylene group form a substituted or unsubstituted C3 to C6 ring;
- and
- R4, R5, R7, R8, R9, R10 R11 and R12 are each independently hydrogen, fluorine, chlorine, bromine, iodine or a hydroxyl, alkoxy, phenoxy, alkyl, alkenyl, alkynyl, aryl, heteroaryl or arylalkyl group.
A composition comprising a compound of formula XIV, XV or XVI;
- or a pharmaceutically acceptable salt thereof wherein,
- each X is independently O or S;
- R1 is hydrogen or an alkyl, alkenyl, alkynyl, aryl, heteroaryl or arylalkyl group;
- R2 is hydrogen or a hydroxyl, alkoxy, phenoxy, alkyl, alkenyl, alkynyl, aryl, heteroaryl or arylalkyl group;
- each R3 and each R6 is:
- (i) independently hydrogen, fluorine, chlorine, bromine, iodine or a hydroxyl, alkoxy, phenoxy, alkyl, alkenyl, alkynyl, aryl, heteroaryl or arylalkyl group;
- or (ii) the two R6 moieties and/or the two R3 moieties taken together with an alkylene, alkenylene or alkynylene group form a substituted or unsubstituted C3 to C6 ring;
- and
- R4, R5, R7, R8, R9, R10 R11 and R12 are each independently hydrogen, fluorine, chlorine, bromine, iodine or a hydroxyl, alkoxy, phenoxy, alkyl, alkenyl, alkynyl, aryl, heteroaryl or arylalkyl group.
A method comprising administering to a subject, to inhibit or treat LSF in said subject, an effective amount of a compound of structural formula XIV, XV or XVI;
- or a pharmaceutically acceptable salt thereof, wherein,
- each X is independently O or S;
- R1 is hydrogen or an alkyl, alkenyl, alkynyl, aryl, heteroaryl or arylalkyl group;
- R2 is hydrogen or a hydroxyl, alkoxy, phenoxy, alkyl, alkenyl, alkynyl, aryl, heteroaryl or arylalkyl group;
- each R3 and each R6 is:
- (i) independently hydrogen, fluorine, chlorine, bromine, iodine or a hydroxyl, alkoxy, phenoxy, alkyl, alkenyl, alkynyl, aryl, heteroaryl or arylalkyl group;
- or (ii) the two R6 moieties and/or the two R3 moieties taken together with an alkylene, alkenylene or alkynylene group form a substituted or unsubstituted C3 to C6 ring;
- and
- R4, R5, R7, R8, R9, R10 R11 and R12 are each independently hydrogen, fluorine, chlorine, bromine, iodine or a hydroxyl, alkoxy, phenoxy, alkyl, alkenyl, alkynyl, aryl, heteroaryl or arylalkyl group.
Dependencies are inferred from the claim text.